Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Summary not available.
Summary not available.
Walgreens Boots Alliance (Nasdaq: WBA) will participate in the 2nd Annual Wolfe Research Healthcare Conference on November 19 at 1:10 p.m. Eastern time. Co-COO Alex Gourlay and CFO James Kehoe will represent the company.
The virtual event will be accessible via the company's investor relations website. WBA is a global leader in pharmacy and has over 21,000 stores across more than 25 countries, employing over 450,000 individuals. The company, recognized for its healthcare contributions, aims to promote healthier lives globally.
Walgreens Boots Alliance (Nasdaq: WBA) and McKesson Corporation (NYSE: MCK) have finalized their joint venture to merge their pharmaceutical wholesale businesses in Germany, creating Alliance Healthcare Deutschland. WBA retains a 70% controlling equity interest, while McKesson holds 30%. This partnership aims to enhance pharmaceutical distribution, support pharmacists, and innovate services within the German healthcare landscape. Both companies express optimism about operational success and improved healthcare delivery.
Walgreens Boots Alliance (Nasdaq: WBA) announced the appointment of Valerie Jarrett to its board of directors and audit committee, effective immediately. Jarrett, an independent director and the first African-American woman on the board, brings a wealth of experience from her roles in high-profile organizations, including Lyft and the Obama Foundation. Her appointment aligns with WBA's goals for diversity and inclusion, enhancing the board's perspective at a critical time for the company. This strategic move aims to strengthen the company’s leadership amidst evolving healthcare demands.
Walgreens Boots Alliance (Nasdaq: WBA) announced a quarterly dividend of 46.75 cents per share, unchanged from the previous quarter but a 2.2% increase from last year. This dividend will be paid on December 11, 2020, to shareholders on record as of November 19, 2020. The company has a long-standing commitment to dividends, having paid them for 352 consecutive quarters and raised them for 45 consecutive years. Walgreens Boots Alliance continues to be a leader in the pharmacy sector, serving millions of customers globally.
Walgreens expands its COVID-19 testing program to include children aged 3 and older, enhancing access to testing services across the U.S. Previously, testing was limited to those aged 18 and over. With approximately 620 testing sites currently operational and an additional 80 set to open, Walgreens aims to support communities, particularly those identified as socially vulnerable by the CDC. Testing is provided at no cost for eligible individuals and results are typically available within 24 to 72 hours. This initiative underscores Walgreens' commitment to community health during the pandemic.
Walgreens Boots Alliance (WBA) reported fiscal Q4 2020 earnings with a net profit drop of 44.9% to $373 million, and EPS down 42.8% to $0.43, largely impacted by COVID-19. Adjusted net earnings fell 30.9% to $887 million, and sales rose 2.3% to $34.7 billion. For the full fiscal year, net earnings decreased 88.5% to $456 million, with adjusted EPS at $4.74, down 20.8%. WBA anticipates low single-digit growth in adjusted EPS for fiscal 2021, with strategic investments focused on customer-centric improvements and omnichannel capabilities.
Walgreens Boots Alliance (Nasdaq: WBA) announced that Ornella Barra, Co-Chief Operating Officer, was commended for her sustainability leadership at the Responsible Business Awards 2020. The award recognizes her dedication to community health and innovation. Ms. Barra, who chairs WBA’s Corporate Social Responsibility (CSR) Committee, emphasized the company's commitment to building healthy communities and sustainable practices, especially during the pandemic. Under her leadership, WBA has achieved multiple awards, including the Global Leadership Award by the UN Foundation.
Asembia and Walgreens have announced an enhanced collaboration through a new group purchasing organization (GPO) solution. This partnership aims to foster efficiencies and create innovative pharmaceutical contracts. Asembia will serve as the primary GPO, negotiating specialty pharmacy contracts that leverage technology and supply chain management. This move is intended to provide increased value to pharmaceutical manufacturers and enhance Walgreens' offerings. The collaboration builds on a 15-year relationship and is designed to adapt to changing healthcare delivery dynamics.